BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 38745186)

  • 1. Tumour-derived exosome SNHG17 induced by oestrogen contributes to ovarian cancer progression via the CCL13-CCR2-M2 macrophage axis.
    Liang H; Geng S; Wang Y; Fang Q; Xin Y; Li Y
    J Cell Mol Med; 2024 May; 28(9):e18315. PubMed ID: 38680032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stimulation of exosome generation by visfatin polarizes M2 macrophages and enhances the motility of chondrosarcoma.
    Song CY; Wu CY; Lin CY; Tsai CH; Chen HT; Fong YC; Chen LC; Tang CH
    Environ Toxicol; 2024 Jul; 39(7):3790-3798. PubMed ID: 38497692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro and In Vivo Evaluation of the Effects of Drug 2c and Derivatives on Ovarian Cancer Cells.
    Maddaloni M; Farra R; Dapas B; Felluga F; Benedetti F; Berti F; Drioli S; Vidali M; Cemazar M; Kamensek U; Brancolini C; Murano E; Maremonti F; Grassi M; Biasin A; Rizzolio F; Cavarzerani E; Scaggiante B; Bulla R; Balduit A; Ricci G; Zito G; Romano F; Bonin S; Azzalini E; Baj G; Tierno D; Grassi G
    Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated β-catenin activation.
    Wang M; Sun Y; Gu R; Tang Y; Han G; Zhao S
    J Ovarian Res; 2024 May; 17(1):101. PubMed ID: 38745186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2.
    Yuan L; Wang Y; Chen Y; Chen X; Li S; Liu X
    Int Immunopharmacol; 2023 Aug; 121():110401. PubMed ID: 37302371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monocyte and Macrophage in Neuroblastoma: Blocking Their Pro-Tumoral Functions and Strengthening Their Crosstalk with Natural Killer Cells.
    Vitale C; Bottino C; Castriconi R
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising Nanomedicines of Shikonin for Cancer Therapy.
    Yan C; Li Q; Sun Q; Yang L; Liu X; Zhao Y; Shi M; Li X; Luo K
    Int J Nanomedicine; 2023; 18():1195-1218. PubMed ID: 36926681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shikonin enhances chemosensitivity of oral cancer through β-catenin pathway.
    Xiang Y; Si L; Zheng Y; Wang H
    Oral Dis; 2024 Mar; 30(2):433-447. PubMed ID: 36453015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shikonin Mediates Apoptosis through G Protein-Coupled Estrogen Receptor of Ovarian Cancer Cells.
    Liu X; Yang Y; Tang X; Guo L; Tang X; Zhu T; Zhao T; Zhang W; Zhang P
    Evid Based Complement Alternat Med; 2022; 2022():6517732. PubMed ID: 36248433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
    Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
    Front Immunol; 2022; 13():994019. PubMed ID: 36177006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
    Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
    Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy.
    Jin C; Yuan M; Bu H; Jin C
    J Oncol; 2022; 2022():4880355. PubMed ID: 35466318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PKM2 Enhances Sensitivity of Olaparib to Ovarian Cancer Cells and Induces DNA Damage.
    Zhou S; Li D; Xiao D; Wu T; Hu X; Zhang Y; Deng J; Long J; Xu S; Wu J; Li G; Peng M; Yang X
    Int J Biol Sci; 2022; 18(4):1555-1568. PubMed ID: 35280680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.
    Sun B; Xu L; Bi W; Ou WB
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twist1 regulates macrophage plasticity to promote renal fibrosis through galectin-3.
    Wu Q; Sun S; Wei L; Liu M; Liu H; Liu T; Zhou Y; Jia Q; Wang D; Yang Z; Duan M; Yang X; Gao P; Ning X
    Cell Mol Life Sci; 2022 Feb; 79(3):137. PubMed ID: 35182235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive Oxygen Species-Mediated Cytotoxicity in Liver Carcinoma Cells Induced by Silver Nanoparticles Biosynthesized Using
    Hailan WA; Al-Anazi KM; Farah MA; Ali MA; Al-Kawmani AA; Abou-Tarboush FM
    Nanomaterials (Basel); 2022 Jan; 12(1):. PubMed ID: 35010111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities.
    Liu J; Xiao Q; Xiao J; Niu C; Li Y; Zhang X; Zhou Z; Shu G; Yin G
    Signal Transduct Target Ther; 2022 Jan; 7(1):3. PubMed ID: 34980884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shikonin, a naphthalene ingredient: Therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches.
    Sun Q; Gong T; Liu M; Ren S; Yang H; Zeng S; Zhao H; Chen L; Ming T; Meng X; Xu H
    Phytomedicine; 2022 Jan; 94():153805. PubMed ID: 34749177
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.